Social Determinants of Health Tied to Atherosclerotic CVD Risk
By Lori Solomon HealthDay Reporter
WEDNESDAY, May 1, 2024 -- Both individual- and area-level social determinants of health (SDOH) are associated with atherosclerotic cardiovascular disease (ASCVD) risk, according to a study published online April 26 in JAMA Network Open.
Mengying Xia, M.P.H., from Columbia University in New York City, and colleagues examined the association of SDOH at both individual and area levels with ASCVD risks. The analysis included 26,316 participants (aged 40 to 79 years without a history of ASCVD) from four large U.S. cohort studies, with baseline data collected from 1995 to 2007 and a median follow-up of 13.0 years.
The researchers found that 44.7 percent had at least one adverse individual-level SDOH and 41.5 percent had at least one adverse area-level SDOH. At both the individual and area levels, SDOH, including low education, low income, and unemployment, were associated with an increased risk for ASCVD. Model discrimination did not change by adding area-level SDOH alone to the pooled cohort equations (PCEs) but modestly improved calibration. There were modest improvements in both discrimination and calibration when adding both individual- and area-level SDOH to the PCEs among non-Hispanic Black individuals (change in C index, 0.0051; change in scaled integrated Brier score [IBS], 0.396 percent), as well as improvement in calibration in White individuals (change in scaled IBS, 0.274 percent).
"Both individual- and area-level SDOH may be considered in future development of ASCVD risk assessment tools, particularly among Black individuals," the authors write.
One author reported owning stock in MedExplain.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.